Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Benchtop Bioreactor

By Drug Discovery Trends Editor | April 6, 2010

The Automation Partnership (TAP), a leader in the design and development of innovative automation for life science applications, is pleased to announce its new advanced micro bioreactor system (ambr).

ambr replicates the characteristics of classical bioreactors at microscale (10 – 15 ml working volume), by using cost effective, disposable micro bioreactors controlled by an automated workstation. It enables the rapid evaluation of multiple bioreactor cultures (24 in parallel), improving productivity in cell line development with significant savings on materials and labour.

Dr Richard Wales, TAP’s Technology Director for ambr, will be presenting exciting data from independent trials of CHO cells expressing an antibody construct. This includes data from testing carried out at major biotechnology companies, with comparison to both 5 and 10 litre bioreactors, and demonstrates the potential of ambr as a new, cost-effective route for cell line selection and early process development.

Dr Richard Wales stated:” The infrastructure requirements, overheads and labour costs of working with bench-scale bioreactors limits their use in many organisations. We are delighted to have developed a solution to this problem that not only saves time by automating set-up, sampling and maintenance of 24 individual disposable bioreactors, but also really mimics the physical characteristics of a classical bioreactor.”

Dr Wales added: “We look forward to discussing our exciting proof-of concept data with bioprocess scientists looking for intelligent, new approaches to improve their cell line selection and process development.”

The Automation Partnership


Filed Under: Drug Discovery

 

Related Articles Read More >

S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
Drug companies sign “Most Favored Nation” deals, then raise prices anyway
New gonorrhea antibiotic could treat resistant infections
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE